Focus: Alto Neuroscience is an AI-driven biotechnology company focused on developing brain biomarkers to match patients with psychiatric and neurological therapies. The company is publicly traded and headquartered in Mountain View, CA, with a concentrated pipeline in Major Depressive Disorder.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Alto Neuroscience to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alto Neuroscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Alto Neuroscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+1 more
Alto Neuroscience Adds Karuna Therapeutics Founder Andrew Miller to Board of Directors - citybiz
Alto Neuroscience Adds Karuna Therapeutics Founder Andrew Miller to Board of Directors citybiz
Alto Says Investors Use Hindsight In Suit Over Drug Trial - Law360
Alto Says Investors Use Hindsight In Suit Over Drug Trial Law360
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug - MSN
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug MSN
Alto Neuroscience launches phase 2b trial for depression drug - Investing.com
Alto Neuroscience launches phase 2b trial for depression drug Investing.com
California Biotech Co. Advances Depression Drug Breakthrough - Streetwise Reports
California Biotech Co. Advances Depression Drug Breakthrough Streetwise Reports
Alto suffers mid-stage blow in schizophrenia, ramps up depression drug - FirstWord PHARMA
Alto suffers mid-stage blow in schizophrenia, ramps up depression drug FirstWord PHARMA
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo